ABSTRACT
This chapter summarizes the results of treatment trials with ergots and 5-HT1B/Dagonists (triptans) for the treatment of acute migraine attacks. A comparison between antimigraine drugs is only possible in randomized controlled trials (RCTs) with head-to-head comparisons. When direct comparisons are not available, indirect, although less reliable, information can be gained by comparing net therapeutic gain. Therapeutic gain is the difference in efficacy between active drug and placebo (1). Another way to indirectly compare the different triptans is a meta-analysis (2,3).
